Презентация доклада в рамках Санкт-Петербургского Международного Форума по фармацевтике и биотехнологиям IPhEB "Опыт применения образовательной программы Йельского университета"
This document outlines a presentation on clinical research and development challenges and opportunities. It discusses the low productivity and increasing costs of R&D, potential loss of revenue from expiring patents, and reasons for low productivity such as target and trial design issues. It also covers trends like globalization of clinical trials to reduce costs and access large patient populations. Finally, it discusses the need for quality and qualified investigators to address the supply and demand imbalance.
Jim Connolly of Wyeth Vaccines presented at the Bear Stearns Healthcare Conference on September 10, 2007. The presentation highlighted that Wyeth is a leader in vaccines with a focus on future growth opportunities, particularly in the pneumococcal disease area for infants and adults. Wyeth developed the first "blockbuster" vaccine Prevnar, which has been highly effective in reducing pneumococcal disease in both children and adults through herd immunity. The company has a strong pipeline of innovative vaccine candidates poised to drive significant future growth.
This document outlines an agenda for a joint meeting between BASF and Monsanto on collaboration efforts around increasing crop yields and stress tolerance. The agenda includes presentations on current collaboration projects between the companies, workshops on pipeline valuation, and discussions on identifying genes that can increase yields. The collaboration aims to develop traits for corn, soybeans, cotton and canola that improve stress tolerance and yields through a joint research pipeline and commercialization through Monsanto's channels. Key updates provided include over 90 lead genes identified through the collaboration and over 12 million data points collected from field tests of yield and stress events.
Biomarkers are increasing the success rates of drug development and reducing costs by helping to identify failures earlier. They allow pharmaceutical companies to streamline clinical trials, make better decisions about drug candidates, and potentially develop personalized medicines to match patients with optimal treatments. While the initial costs of biomarker research and validation are high, biomarkers are expected to generate substantial savings over the long term through more efficient drug development and higher success rates.
This document provides an overview of biopharmaceutical manufacturing outsourcing to Asia. It discusses the complexities of biopharmaceutical production and why many companies outsource this work. It outlines key considerations for choosing a contract manufacturing organization (CMO) in Asia, including ensuring cGMP compliance, technical competence, intellectual property protection, and effective communication. The document briefly reviews the history of bioprocessing in Asia and provides examples of current CMOs in various Asian countries with relevant production capabilities.
This presentation promotes social media marketing services from MrPepperMarketing and emphasizes the importance of social media for businesses. It provides statistics on social media usage and examples of businesses that increased revenue and traffic through social media. The presentation argues that while major corporations benefit from social media, small businesses can also compete by utilizing free social media tools and outsourcing management to a social media marketer. It highlights case studies of businesses that succeeded using social media and promises increased leads, referrals, exposure, and money for clients who hire MrPepperMarketing's social media services.
This document outlines a presentation on clinical research and development challenges and opportunities. It discusses the low productivity and increasing costs of R&D, potential loss of revenue from expiring patents, and reasons for low productivity such as target and trial design issues. It also covers trends like globalization of clinical trials to reduce costs and access large patient populations. Finally, it discusses the need for quality and qualified investigators to address the supply and demand imbalance.
Jim Connolly of Wyeth Vaccines presented at the Bear Stearns Healthcare Conference on September 10, 2007. The presentation highlighted that Wyeth is a leader in vaccines with a focus on future growth opportunities, particularly in the pneumococcal disease area for infants and adults. Wyeth developed the first "blockbuster" vaccine Prevnar, which has been highly effective in reducing pneumococcal disease in both children and adults through herd immunity. The company has a strong pipeline of innovative vaccine candidates poised to drive significant future growth.
This document outlines an agenda for a joint meeting between BASF and Monsanto on collaboration efforts around increasing crop yields and stress tolerance. The agenda includes presentations on current collaboration projects between the companies, workshops on pipeline valuation, and discussions on identifying genes that can increase yields. The collaboration aims to develop traits for corn, soybeans, cotton and canola that improve stress tolerance and yields through a joint research pipeline and commercialization through Monsanto's channels. Key updates provided include over 90 lead genes identified through the collaboration and over 12 million data points collected from field tests of yield and stress events.
Biomarkers are increasing the success rates of drug development and reducing costs by helping to identify failures earlier. They allow pharmaceutical companies to streamline clinical trials, make better decisions about drug candidates, and potentially develop personalized medicines to match patients with optimal treatments. While the initial costs of biomarker research and validation are high, biomarkers are expected to generate substantial savings over the long term through more efficient drug development and higher success rates.
This document provides an overview of biopharmaceutical manufacturing outsourcing to Asia. It discusses the complexities of biopharmaceutical production and why many companies outsource this work. It outlines key considerations for choosing a contract manufacturing organization (CMO) in Asia, including ensuring cGMP compliance, technical competence, intellectual property protection, and effective communication. The document briefly reviews the history of bioprocessing in Asia and provides examples of current CMOs in various Asian countries with relevant production capabilities.
This presentation promotes social media marketing services from MrPepperMarketing and emphasizes the importance of social media for businesses. It provides statistics on social media usage and examples of businesses that increased revenue and traffic through social media. The presentation argues that while major corporations benefit from social media, small businesses can also compete by utilizing free social media tools and outsourcing management to a social media marketer. It highlights case studies of businesses that succeeded using social media and promises increased leads, referrals, exposure, and money for clients who hire MrPepperMarketing's social media services.
Strategies and Opportunities of Outsourcing -Product Development and Manufact...daisyrmuzzio
This document discusses strategies and opportunities for outsourcing pharmaceutical product development and manufacturing services from Latin America. It notes that Latin America has the potential to become a key global outsourcing hub for these activities in the next 5-10 years due to benefits like industry growth, innovation, and capabilities to address local health needs. It highlights several Latin American countries' strengths in areas like clinical research capabilities, manufacturing infrastructure, and a growing biotech industry. It also discusses expectations for the region to close gaps in areas like regulatory environments and intellectual property protections.
This document discusses Actelion Pharmaceuticals' desire to partner its S1P1 agonist program. It provides background on Actelion and the program. It then discusses trends in pharmaceutical partnering over the last 30 years, with alliances rising to displace other forms of partnerships. The document goes on to describe a stage-gate approach to identify potential partner candidates. It applies scoring tools and risk analysis to 6 firms to identify the most appropriate partners for due diligence.
Global Pharmaceuticals & Biotechnology IndustryGavin Pathross
This research service presents the CEO 360 Degree Perspective for the global pharmaceuticals and biotechnology industry in 2009. It is an amalgamation of research from more than 50 Pharmaceutical research services generated by Frost & Sullivan, customer research findings based on approximately 1,000 end-user interviews approximately 50,000 hours of analyst research, in the last 2 years. Global healthcare analysts from Frost & Sullivan have contributed their market knowledge to cover the most important issues that are relevant in the healthcare industry today. The report also includes research findings from econometric, advanced technology and several other business divisions of Frost & Sullivan.
Will Biosimilars Be A Driver For InnovationAjaz Hussain
The Biosimilar debate touches upon several important reasons for innovation failure in a regulated environment – successful, scientific, resolution will be important for the entire sector.
This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 101 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biom
Bridging The Valley Of Death A Tale Of Two Culturesrwmalonemd
This document discusses the challenges of transitioning biotechnology discoveries from research to commercial products, known as crossing the "valley of death". It notes that on average only 1 in 4 to 1 in 5 biotechnology products in development achieve approval due to fundamental differences between the cultures of research and product development. Bridging this gap requires addressing regulatory, capital, and project management challenges throughout the product development process. The future of biotechnology will rely on rigorous project planning, outsourcing, earlier consideration of development pathways, and continual engagement between research and development teams.
Emerging trends in pharmaceutical industry 2012Ourania Koumi
1. The top 10 pharmaceutical companies by revenue in 2004 and 2011 are listed, with some companies changing ranks and Pfizer remaining the top company.
2. While the industry appears prosperous, the document notes that nothing could be further from the truth and asks the reader to find out why.
3. The pharmaceutical industry faces challenges from changes in the external environment including the economy, political structures, independent auditing bodies, payors, social factors, cultural forces, distributors, and technology. It also faces opportunities in specialty medicines, emerging economies, and customer-centric services.
This document summarizes John Hammergren's presentation at the 2002 Bear Stearns Healthcare Conference. The presentation discusses McKesson's strategies and financial performance. It highlights that McKesson provides pharmaceutical and medical supplies distribution, clinical software, and other healthcare IT solutions. It also notes McKesson's focus on driving automation, generics sales, and clinical leadership to improve margins and execution. Finally, it summarizes McKesson's strong financial performance over the previous quarters with continued revenue and earnings growth.
Evolving Operational Business Model in Pharmaceutical IndustrySurya Chitra,PhD MBA
The pharmaceutical industry is changing its business and operational models due to various pressures. The current model of vertical integration from research to pharmacy is shifting to a more fragmented model. Key drivers include rising costs, price pressures, increased regulation, and patent expirations. The industry must address these issues to sustain growth and profits. Alternative business strategies are needed due to instability in the current blockbuster drug model, which relies on a few highly profitable drugs to offset research and development costs.
Pfizer Canada is exploring public-private partnerships and open innovation models to address gaps in drug innovation. These models include pre-competitive research partnerships and consortia involving multiple companies, universities, and research institutions. They aim to leverage diverse scientific capabilities and resources to make progress on understanding disease biology and developing new treatments. By sharing knowledge and resources in a pre-competitive space, these partnerships seek to accelerate innovation for the benefit of patients while also engaging industry, academia and government.
The document discusses strategies for developing biosimilars in a cost-effective manner. It notes that while the biopharmaceutical opportunity is large, biosimilar development faces significant challenges related to regulation, manufacturing complexity, and marketing limitations. Companies therefore pursue various strategies like building internal capabilities, outsourcing non-core functions, partnering, and acquisitions. The document uses Reliance Life Sciences as a case study, outlining its multi-pronged approach to developing an integrated biosimilars pipeline and capabilities through both internal investment and external partnerships and deals.
The document discusses emerging business and operational models in the pharmaceutical industry. It notes that the traditional vertically integrated model is shifting to a more fragmented model. It also discusses factors driving changes like rising costs and competition. The document analyzes current blockbuster and niche models and potential future models involving more specialization. It proposes a "progressive drug development model" to reduce risks and costs through targeted development.
This document provides information about the Medical Device Manufacturing Summit taking place on June 25-26, 2015 at the Red Rock Resort & Spa in Las Vegas, NV. The summit will feature keynote presentations, case studies, and panels from industry experts on topics such as talent development, supply chain management, and innovation. Over 150 senior medical device executives will attend to network with solution providers and learn best practices. The invitation-only event is designed to facilitate productive business meetings and discussions in an informal setting.
Global Sterilization Systems & Equipment IndustryReportLinker.com
This report analyzes the worldwide markets for Sterilization Systems & Equipment in US$ Million by the following segments: Steam/Autoclave, Ethylene Oxide, Gas Plasma, Gamma Radiation, E-Beam Radiation, Other Methods, and Sterilization Supplies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 143 companies including many key and niche players such as 3M Company, Advanced Sterilization Products, Cantel Medical Corp, Minntech Corporation, Getinge AB, L3 Pulse Sciences, SteriGenics International, Inc., STERIS Corporation, TSO3, and Tuttnauer Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
This document ranks 51 pharmaceutical brands based on their digital competence, or "Digital IQ", across 8 disease states. The brands were evaluated based on their website platform, off-platform messaging, search engine optimization, and social media presence. The top brands like Viagra, Nexium and Chantix were rated as "genius" for having highly optimized, interactive websites and strong digital marketing campaigns. Most brands were average or below, indicating opportunities for most to improve their online strategies and digital capabilities.
This document analyzes the digital competence of 51 pharmaceutical brands across eight disease states. It ranks the brands based on their "Digital IQ" scores, which are calculated based on factors like the effectiveness of their websites, off-platform messaging efforts, search engine optimization, and social media presence. The top brands have highly optimized websites that are engaging and interactive, advertise widely online, and experiment with social media. Most pharmaceutical companies still have room for improvement in their digital strategies.
Biotech Resources Group provides staffing services for clinical research, regulatory, and biologics manufacturing positions. Founded in 2000, the company has direct experience in human resources and large-scale commercial biologics manufacturing. Biotech Resources Group helps biotech, pharmaceutical, and contract research organization clients fill positions and meet project targets through their expertise in recruiting and network in good manufacturing practices. Susan Valdes is the founder and president of Biotech Resources Group, located in Gaithersburg, Maryland.
Ws from innovation to commercialisation marcel van der sluisIventus
Presentation of dr. Marcel van der Sluis, Manager BD Drug Development Cluster at the Workshop 'From Innovation to Commercialisation' during the Dutch Life Sciences & Health Conference 2010
This document discusses how the increased generation of data in pharmaceutical R&D has failed to improve productivity due to an inability to properly organize and apply knowledge. It describes how existing integration strategies store data in isolated "silos" that are difficult to access and compare. The author argues that new semantic technologies based on ontologies can better integrate knowledge across discovery, development, and other business areas to improve transparency, safety monitoring, and decision making.
This report analyzes the worldwide markets for Imaging Agents in US$ Million by the following product segments - Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 55 companies including many key and niche players such as AMAG Pharmaceuticals Inc., Bayer Schering Pharma AG, Bracco Group, Covidien, Cytogen Corp., Daiichi Sankyo Company Limited, Eisai Co., Ltd, GE Healthcare, Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Strategies and Opportunities of Outsourcing -Product Development and Manufact...daisyrmuzzio
This document discusses strategies and opportunities for outsourcing pharmaceutical product development and manufacturing services from Latin America. It notes that Latin America has the potential to become a key global outsourcing hub for these activities in the next 5-10 years due to benefits like industry growth, innovation, and capabilities to address local health needs. It highlights several Latin American countries' strengths in areas like clinical research capabilities, manufacturing infrastructure, and a growing biotech industry. It also discusses expectations for the region to close gaps in areas like regulatory environments and intellectual property protections.
This document discusses Actelion Pharmaceuticals' desire to partner its S1P1 agonist program. It provides background on Actelion and the program. It then discusses trends in pharmaceutical partnering over the last 30 years, with alliances rising to displace other forms of partnerships. The document goes on to describe a stage-gate approach to identify potential partner candidates. It applies scoring tools and risk analysis to 6 firms to identify the most appropriate partners for due diligence.
Global Pharmaceuticals & Biotechnology IndustryGavin Pathross
This research service presents the CEO 360 Degree Perspective for the global pharmaceuticals and biotechnology industry in 2009. It is an amalgamation of research from more than 50 Pharmaceutical research services generated by Frost & Sullivan, customer research findings based on approximately 1,000 end-user interviews approximately 50,000 hours of analyst research, in the last 2 years. Global healthcare analysts from Frost & Sullivan have contributed their market knowledge to cover the most important issues that are relevant in the healthcare industry today. The report also includes research findings from econometric, advanced technology and several other business divisions of Frost & Sullivan.
Will Biosimilars Be A Driver For InnovationAjaz Hussain
The Biosimilar debate touches upon several important reasons for innovation failure in a regulated environment – successful, scientific, resolution will be important for the entire sector.
This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 101 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biom
Bridging The Valley Of Death A Tale Of Two Culturesrwmalonemd
This document discusses the challenges of transitioning biotechnology discoveries from research to commercial products, known as crossing the "valley of death". It notes that on average only 1 in 4 to 1 in 5 biotechnology products in development achieve approval due to fundamental differences between the cultures of research and product development. Bridging this gap requires addressing regulatory, capital, and project management challenges throughout the product development process. The future of biotechnology will rely on rigorous project planning, outsourcing, earlier consideration of development pathways, and continual engagement between research and development teams.
Emerging trends in pharmaceutical industry 2012Ourania Koumi
1. The top 10 pharmaceutical companies by revenue in 2004 and 2011 are listed, with some companies changing ranks and Pfizer remaining the top company.
2. While the industry appears prosperous, the document notes that nothing could be further from the truth and asks the reader to find out why.
3. The pharmaceutical industry faces challenges from changes in the external environment including the economy, political structures, independent auditing bodies, payors, social factors, cultural forces, distributors, and technology. It also faces opportunities in specialty medicines, emerging economies, and customer-centric services.
This document summarizes John Hammergren's presentation at the 2002 Bear Stearns Healthcare Conference. The presentation discusses McKesson's strategies and financial performance. It highlights that McKesson provides pharmaceutical and medical supplies distribution, clinical software, and other healthcare IT solutions. It also notes McKesson's focus on driving automation, generics sales, and clinical leadership to improve margins and execution. Finally, it summarizes McKesson's strong financial performance over the previous quarters with continued revenue and earnings growth.
Evolving Operational Business Model in Pharmaceutical IndustrySurya Chitra,PhD MBA
The pharmaceutical industry is changing its business and operational models due to various pressures. The current model of vertical integration from research to pharmacy is shifting to a more fragmented model. Key drivers include rising costs, price pressures, increased regulation, and patent expirations. The industry must address these issues to sustain growth and profits. Alternative business strategies are needed due to instability in the current blockbuster drug model, which relies on a few highly profitable drugs to offset research and development costs.
Pfizer Canada is exploring public-private partnerships and open innovation models to address gaps in drug innovation. These models include pre-competitive research partnerships and consortia involving multiple companies, universities, and research institutions. They aim to leverage diverse scientific capabilities and resources to make progress on understanding disease biology and developing new treatments. By sharing knowledge and resources in a pre-competitive space, these partnerships seek to accelerate innovation for the benefit of patients while also engaging industry, academia and government.
The document discusses strategies for developing biosimilars in a cost-effective manner. It notes that while the biopharmaceutical opportunity is large, biosimilar development faces significant challenges related to regulation, manufacturing complexity, and marketing limitations. Companies therefore pursue various strategies like building internal capabilities, outsourcing non-core functions, partnering, and acquisitions. The document uses Reliance Life Sciences as a case study, outlining its multi-pronged approach to developing an integrated biosimilars pipeline and capabilities through both internal investment and external partnerships and deals.
The document discusses emerging business and operational models in the pharmaceutical industry. It notes that the traditional vertically integrated model is shifting to a more fragmented model. It also discusses factors driving changes like rising costs and competition. The document analyzes current blockbuster and niche models and potential future models involving more specialization. It proposes a "progressive drug development model" to reduce risks and costs through targeted development.
This document provides information about the Medical Device Manufacturing Summit taking place on June 25-26, 2015 at the Red Rock Resort & Spa in Las Vegas, NV. The summit will feature keynote presentations, case studies, and panels from industry experts on topics such as talent development, supply chain management, and innovation. Over 150 senior medical device executives will attend to network with solution providers and learn best practices. The invitation-only event is designed to facilitate productive business meetings and discussions in an informal setting.
Global Sterilization Systems & Equipment IndustryReportLinker.com
This report analyzes the worldwide markets for Sterilization Systems & Equipment in US$ Million by the following segments: Steam/Autoclave, Ethylene Oxide, Gas Plasma, Gamma Radiation, E-Beam Radiation, Other Methods, and Sterilization Supplies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 143 companies including many key and niche players such as 3M Company, Advanced Sterilization Products, Cantel Medical Corp, Minntech Corporation, Getinge AB, L3 Pulse Sciences, SteriGenics International, Inc., STERIS Corporation, TSO3, and Tuttnauer Company. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
This document ranks 51 pharmaceutical brands based on their digital competence, or "Digital IQ", across 8 disease states. The brands were evaluated based on their website platform, off-platform messaging, search engine optimization, and social media presence. The top brands like Viagra, Nexium and Chantix were rated as "genius" for having highly optimized, interactive websites and strong digital marketing campaigns. Most brands were average or below, indicating opportunities for most to improve their online strategies and digital capabilities.
This document analyzes the digital competence of 51 pharmaceutical brands across eight disease states. It ranks the brands based on their "Digital IQ" scores, which are calculated based on factors like the effectiveness of their websites, off-platform messaging efforts, search engine optimization, and social media presence. The top brands have highly optimized websites that are engaging and interactive, advertise widely online, and experiment with social media. Most pharmaceutical companies still have room for improvement in their digital strategies.
Biotech Resources Group provides staffing services for clinical research, regulatory, and biologics manufacturing positions. Founded in 2000, the company has direct experience in human resources and large-scale commercial biologics manufacturing. Biotech Resources Group helps biotech, pharmaceutical, and contract research organization clients fill positions and meet project targets through their expertise in recruiting and network in good manufacturing practices. Susan Valdes is the founder and president of Biotech Resources Group, located in Gaithersburg, Maryland.
Ws from innovation to commercialisation marcel van der sluisIventus
Presentation of dr. Marcel van der Sluis, Manager BD Drug Development Cluster at the Workshop 'From Innovation to Commercialisation' during the Dutch Life Sciences & Health Conference 2010
This document discusses how the increased generation of data in pharmaceutical R&D has failed to improve productivity due to an inability to properly organize and apply knowledge. It describes how existing integration strategies store data in isolated "silos" that are difficult to access and compare. The author argues that new semantic technologies based on ontologies can better integrate knowledge across discovery, development, and other business areas to improve transparency, safety monitoring, and decision making.
This report analyzes the worldwide markets for Imaging Agents in US$ Million by the following product segments - Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 55 companies including many key and niche players such as AMAG Pharmaceuticals Inc., Bayer Schering Pharma AG, Bracco Group, Covidien, Cytogen Corp., Daiichi Sankyo Company Limited, Eisai Co., Ltd, GE Healthcare, Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Similar to Форум IPhEB - Марсело Э. Бигаль, компания Merck (20)
Форум IPhEB - Панарин Е.Ф., директор Института высокомолекулярных соединений РАНDiana Larina
Презентация доклада в рамках Санкт-Петербургского Международного Форума по фармацевтике и биотехнологиям IPhEB "Подготовка кадров для биотехнологии и фармацевтики на базе ИВС РАН и кафедры медицинской биотехнологии СПбГПУ"
Форум IPhEB - Гарабаджиу А.В., проректор по научной работе Санкт-Петербургско...Diana Larina
Презентация доклада в рамках Санкт-Петербургского Международного Форума по фармацевтике и биотехнологиям IPhEB " Опыт подготовки специалистов-технологов широкого профиля для биофармацевтической промышленности"
Презентация доклада в рамках Санкт-Петербургского Международного Форума по фармацевтике и биотехнологиям IPhEB "Международная гармонизация в регулировании лекарственного рынка"
Форум IPhEB - Дмитриев В.А., директор АРФПDiana Larina
Презентация доклада на Санкт-Петербургском Международном Форуме по фармацевтике и биотехнологиям IPhEB (26 - 28 апреля 2011).
"Подведение итогов 2010 года, анализ развития отрасли и государственной политики в регионах Российской Федерации и в мире"
Форум IPhEB - Иващенко А.А., председатель Совета директоров ЦВТ «ХимРар»Diana Larina
Презентация доклада на Санкт-Петербургском Международном Форуме по фармацевтике и биотехнологиям IPhEB (26-28 апреля 2011)
"Университетские кластеры как основной инновационный механизм реализации Стратегий развития Медпром и Фарма 2020"
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)MuskanShingari
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
Dr. Tan's Balance Method.pdf (From Academy of Oriental Medicine at Austin)GeorgeKieling1
Home
Organization
Academy of Oriental Medicine at Austin
Academy of Oriental Medicine at Austin
Academy of Oriental Medicine at Austin
About AOMA: The Academy of Oriental Medicine at Austin offers a masters-level graduate program in acupuncture and Oriental medicine, preparing its students for careers as skilled, professional practitioners. AOMA is known for its internationally recognized faculty, award-winning student clinical internship program, and herbal medicine program. Since its founding in 1993, AOMA has grown rapidly in size and reputation, drawing students from around the nation and faculty from around the world. AOMA also conducts more than 20,000 patient visits annually in its student and professional clinics. AOMA collaborates with Western healthcare institutions including the Seton Family of Hospitals, and gives back to the community through partnerships with nonprofit organizations and by providing free and reduced price treatments to people who cannot afford them. The Academy of Oriental Medicine at Austin is located at 2700 West Anderson Lane. AOMA also serves patients and retail customers at its south Austin location, 4701 West Gate Blvd. For more information see www.aoma.edu or call 512-492-303434.
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...Donc Test
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Jim Jacob Roy
In this presentation , SBP ( spontaneous bacterial peritonitis ) , which is a common complication in patients with cirrhosis and ascites is described in detail.
The reference for this presentation is Sleisenger and Fordtran's Gastrointestinal and Liver Disease Textbook ( 11th edition ).
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Nutritional deficiency Disorder are problems in india.
It is very important to learn about Indian child's nutritional parameters as well the Disease related to alteration in their Nutrition.
Pictorial and detailed description of patellar instability with sign and symptoms and how to diagnose , what investigations you should go with and how to approach with treatment options . I have presented this slide in my 2nd year junior residency in orthopedics at LLRM medical college Meerut and got good reviews for it
After getting it read you will definitely understand the topic.
“Environmental sanitation means the art and science of applying sanitary, biological and physical science principles and knowledge to improve and control the environment therein for the protection of the health and welfare of the public”.The overall importance of sanitation are to provide a healthy living environment for everyone, to protect the natural resources (such as surface water, groundwater, soil ), and to provide safety, security and dignity for people when they defecate or urinate .Sanitation refers to public health conditions such as drinking clean water, sewage treatment, etc. All the effective tools and actions that help in keeping the environment clean come under sanitation. Sanitation refers to public health conditions such as drinking clean water, sewage treatment. All the effective tools and actions that help in keeping the environment clean and promotes public health is the necessary in todays life.
1. Санкт-Петербургский Международный
Форум по Фармацевтике и Биотехнологиям
Knowledge Sharing on Drug Development
- the Merck/Yale Initiative
Marcelo E. Bigal, M.D., Ph.D.
Head of the Merck Investigator Studies Program and
Scientific Education Group
Office of the Chief Medical Officer
2. Overview
Medical Education and Industry
Challenges Facing Industry and Countries
Principles of Drug Development
The Drug Development Course – the Yale/Merck Initiative.
The St. Petersburg Initiative
3. Background
Regardless of their career path, M.D.’s will be exposed on a daily basis
to issues around pharmacology and drug development, yet they have
little practical knowledge.
Although academic institutions are charged with educating future
medical professionals, expertise in drug development largely resides in
industry (pharmaceutical).
In order to bridge this gap, an ethical and transparent partnership
between academia and industry is critical.
– Serves the public interest
– Students become educated on the complexities of the drug development process
– Patients benefit from sharing of expertise and resources
4. Examples of Physician-Scientist Roles in Industry
Basic and clinical research roles
Outcomes research
Policy
Integrative roles
Externally facing roles
Internal support roles
Senior leadership roles
5. Challenges Facing Industry
Drug development, already an unpredictable and expensive
undertaking, has taken on greater uncertainty.
There are significant implications resulting from the difficulty to
efficiently execute drug development in the United States.
Innovation and advances in therapeutics, which critically
depend on clinical research, are threatened.
6. Multiple Factors Drive Today’s Healthcare
Agenda …
AGING OF RISING PRICING WHO PAYS?
POPULATIONS ALLOCATION OF PRESSURES INDUSTRY vs. GOVT
GDP TO HEALTH
CARE
Health Care
Dynamics REGIONAL
ECONOMIC GROWTH
CREDIT DIFFERENCES
TIGHTENING
EQUITY VALUES
DOWN The BioPharma EMERGENCE
Economic OF
IPO MARKET Crisis Industry Global (BRIC)
Mega-trends
PUBLIC/
PRIVATE
CLOSED SYSTEMS
GOVTS FACING
BIGGER DEFICITS, I/P RECOGNITION
SPENDING BioPharma CHALLENGES
Challenges
PATENT R&D PRODUCTIVITY PIPELINES SHIFTING STAKEHOLDER
EXPIRATIONS LESS CERTAIN ROLES
DEVELOPMENT COSTS/
REQUIREMENTS EVOLVING REENGINEERING OF
SURGING COMMERCIAL MODELS COST STRUCTURES
7. Drug Discovery & Development Is High Risk1,2
1. Lilly Clinical Trial Registry Web Site. http://www.lillytrials.com/docs/education.html. Accessed February 3, 2010.
2. Eye on FDA Web site. http://www.eyeonfda.com/downloads/FDADrugApprovalCommunications.pdf. Accessed February 3, 2010.
3. Watkins KJ. Chem Eng News. 2002;80:27-33.
4. DiMasia JA et al. Manage Decis Econ. 2007;28:469-479.
8. What is Changing in the World of Clinical Research
and Drug Development? – An Industry Perspective
Ballooning Costs of
Research &
Development
Evolving
Deteriorating Capacity Research Partnerships
for Clinical Trial Execution & Regulatory Environment
A Difficult Process
Turns More
Challenging
9. The New Reality: R&D Costs Continue to Rise While
Output Falls
Productivity Trends
BioPharma R&D Spend v. FDA Approvals
60 60
R&D Spend FDA Approvals
50 50
R&D Spend ($ billions)
40 40
37 37 36
# of NCEs
30 30
29 29
27
24 24
22
20 20 20
18
10 10
0 0
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Source: PhRMA, FDA Year
Notes:
1) R&D spend data for PhRMA members
2) FDA approvals reflect new molecular entities and biologics
10. Probability of Success for Investigational Drugs is Small
20% of self-originated new drugs that enter clinical testing will be
FDA-approved.
Clinical Approval Success Rates by Therapeutic Class1
Source: 1Tufts Center for the Study of Drug Development, “New drugs entering clinical testing in top 10 firms jumped 52% in 2003-05,” Impact
Report, 2006.
11. “…over the long run, few issues are as important to a nation’s long term
economic security and global standing as being a leader in moving life
sciences forward.”
- Larry Summers
Financial Times, January 2007*
“…If you think research is expensive,
try disease.”
- Mary Lasker, Health Activist and
Philanthropist (1901-94)*
12. Academia/Government and Industry Roles in R&D:
Complementarity
Private Sector – $65.2B Private sector
outspends NIH 2:1
Clinical
Research
Translational
Clinical Research
“ There is an ecosystem of
science and biotechnology.
Public organizations,
patient organizations,
Research universities, Congress,
Translational “
FDA, all of this is an
Research ecosystem that is envied in
the rest of the world.
Basic Basic
Research – E. Zerhouni,
Research Director of NIH
NIH3 – $29.4B total
– $20.1B research
Sources: 1Burrill & Company, analysis for PhRMA, 2005–2009 (Includes PhRMA research associates and nonmembers) in PhRMA, “Profile 2008,
Pharmaceutical Industry;” PhRMA, “PhRMA Annual Membership Survey,” 1996-2009; 2Adapted from E. Zerhouni, Presentation at Transforming
Health: Fulfilling the Promise of Research, 2007; 3NIH Office of the Budget, “FY 2009 President’s Budget Request Tabular Data”,
http://officeofbudget.od.nih.gov/ui/2008/tabular%20data.pdf
13. New Medicines Increase Longevity
They account for 40% of increase in life expectancy.
Increase in Longevity Due to New Drug
2.5 Launches
Total Increase in Longevity 1.96
Number of Years Increased Longevity
2.0
1.65
1.5 1.37
1.07
1.0
0.76 0.79
0.70
0.57 0.62
0.56
0.5 0.45
0.30
0.23
0.12
0.0
1988 1990 1992 1994 1996 1998 2000
Data source: Lichtenberg8
11
15. Medicines Prevent Cancer Recurrence
New breast cancer drug greatly reduces recurrence and death (5 to 10 Years
After diagnosis in postmenopausal women).
Breast Cancer Recurrence or Death Deaths Due to Breast Cancer
14% 13% 7% 6.6%
Percent of Patients Projected Over 4 Years
12% 6% Death
Rate
5% Almost
10%
Percent of Patients
Halved
8% 7% 4% 3.5%
6% 3%
4% 2%
2% 1%
0% 0%
Placebo New Drug Placebo New Drug
Note: Study halted early in order to provide the drug to all participants.
Data source: Goss et al.15
13
16. U.S. AIDS Deaths Drop Dramatically with Introduction
of New Medicines
18
16.2
16
14
Deaths Per 100,000 People
12
10
8
6 5.3 4.9
4
2
0
1995 1999 2002
(HAART treatment approved)
Data source: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics14
12
17. Response: Increased Allocation of Development
Spending and Patient Accrual in ex-US Regions
Source: Jefferies, CRO Survey, March 2007
18. Overview
Medical Education and Industry
Challenges Facing Industry and Countries
Principles of Drug Development
The Drug Development Course – the Yale/Merck Initiative.
The St. Petersburg Initiative
19. Description of Project
The Drug Development Curriculum is a pioneering initiative between
Yale and Merck that bridges this gap by providing valuable insight into
the drug development process
– Scope and objectives defined by Yale faculty
– Content developed by 34 MDs and PhDs from Merck
– Content revised and approved by Yale faculty
– Course administered and assessed by Yale faculty
– Not related to Merck brands
20. Opportunities Offered
Improve and increase relevancy of the medical school curriculum
around the role of the pharmaceutical industry in drug development
and pharma’s relationship with the academic community.
Convey the value brought by pharma to public health policy in
delivering innovative, differentiated treatment options.
Create a forum for the academia to educate trainees on how to
interact with industry
Communicate that optimizing patient benefits is the result of
collaboration between academia and pharma
Provide an example of meaningful objective collaboration that can
make a difference.
21. Yale Team
James Howe PhD, Course Director of the Pharmacology Course
Department: Pharmacology
Michael DiGiovanna, MD, PhD, Director Pharmacology Curriculum
Department: Cancer Center
Michael L. Schwartz, Associate Prof & Dir Medical Studies Neurobiology
Department: Neurobiology
Gisella Weissbach-Licht, Director of Curriculum Management
Department: Office of Education
22. Course Objective and Theme
The objective of the course is to provide a supplemental program to
existing course work that introduces students to the basic principles of
clinical and translational research, including how such research is
conducted, evaluated, explained to patients, and applied to patient care
Alzheimer’s disease was chosen as a theme to use through the course
– A chemical compound targeting Alzheimer’s was carried through the
phases of drug development to demonstrate an application of the
module’s content (similar to a case study)
23. Course Structure: Modules
Course is divided into 5 modules with 2-5 lessons per module
19 total lessons ~ 9 hours of course time
– Each module introduced by a Merck Senior Subject Matter Expert
(SME)
– Senior SME oversaw the development of each module’s content (34
SMEs contributed to the entire course content)
– A module concludes with a summary by the Senior SME and a
handoff to the Senior SME of the subsequent module.
– Every lesson includes Knowledge Check questions as assessment
of the content
24. Course Structure: Modules (cont’d)
How New Drugs Are Discovered
– 5 Lessons
– Duration: 2 hours 30 minutes
Considerations for Testing a New Drug in Humans
– 3 Lessons
– Duration : 2 hours
How Investigational Drugs Are Tested in Humans
– 4 Lessons
– Duration : 2 hours
Regulatory Review Process for New Drugs
– 5 Lessons
– Duration : 1 hour 30 minutes
Post-Approval Activities
– 2 Lessons
– Duration : 1 hour 15 minutes
25. Module 1: How Are New Drugs Discovered?
Overall module length ~ 2 ½ hours
5 Lessons
1) Target Identification
2) Target Validation
3) Lead Identification
4) Lead Optimization
5) Biologics
26. The Basic Process of Drug Discovery –
Target Identification
Target Target Lead Lead
ID Opt Post -PCC
ID Val
Biomarkers
The high degree of risk in selecting the “right” drug targets demands a
strategy based on high attrition rate.
Target ID
8 weeks to evaluate a target
1000s
of Diseases 1
Medical need? Modern
Strategy? 1000s biology
& 100s Target Validation
10,000s ”-omics”
of biological
molecules Informed
Choice
Informed
Choice
27.
28.
29.
30.
31. PCC Criteria for Approval Into Development
Proof of Efficacy
– In vitro potency
– In vitro selectivity
– Efficacy readout in animals
– Target engagement
– Disease markers
Proof of Safety
– Ancillary pharmacology
– Metabolism data
– Panlab results
– Dose limiting toxicity (DLT) studies
Merck Research Labs, Whitehouse Station, NJ.
32. Module 2: Considerations for Testing a Drug on
Humans
Overall module length ~2 hours
3 Lessons
1) Formulation activities to support drug development activities
up to PhI
2) Drug metabolism and pharmacokinetics
3) Non-clinical safety assessment in vitro & in vivo and
toxicokinetics
33. Why Formulate ?
Provide patient with convenient dosage
form Stability
– Preferably once/day dosing
– Taste masking (e.g. film coat)
Drug
Processability
Stabilize the API (Shelf life target 3 years Absorption
at RT)
Optimize drug absorption in the GI tract PK Profile
Achieve desired PK profile
– Improve therapeutic index
Robust/scaleable manufacturing process
34.
35. “Ideal” Drug Candidate – DMPK Point of View
Good aqueous solubility for IV formulation and oral absorption
High bioavailability and acceptable PK characteristics for intended route
Small “first-pass” effect (liver/gut wall)
“Balanced” clearance:
– Renal excretion of intact drug
– Biliary elimination of intact drug
– Metabolism to limited number of products
No pharmacologically active metabolites (unless prodrug)
No chemically reactive metabolites (toxicity issues)
Minimal CYP induction (drug interaction liability)
Minimal CYP inhibitory potential (especially mechanism based)
Metabolism should be catalyzed by multiple CYP enzymes
– e.g., CYP3A4, 2C9, 1A2
Metabolism should not depend largely on a polymorphically expressed enzyme
– e.g., CYP2D6, 2C19
Minimal Pgp activity (central nervous system programs)
DMPK = drug metabolic and pharmacokinetic; IV = intravenous; PK = pharmacokinetic; CYP = cytochrome P450; Pgp = P-Glycoprotein.
Merck Research Labs, Whitehouse Station, NJ.
36. Non-mechanism-based Toxicity
Occurs when the compound, or one of its metabolites, interacts with a molecule other than the
intended target
Common problems
– Ion channels
– Protein modifications
– Uptake inhibition
– Metabolic clearance pathways: inhibition or activation
– Mutagenicity, genotoxicity
Idiosyncratic problems: can be anything
Tools
– Experience, institutional memory
– Identify off-target hits early: Panlabs
– Modeling for common problems
– Animal models
– Expression profiling
Merck Research Labs, Whitehouse Station, NJ.
37. Ancillary Pharmacology and Special Safety
Assessment Studies
Ancillary Pharmacology; full panel consists of1:
– Cardiovascular dog study
– Respiratory dog study
– Renal dog study
– Central nervous system (CNS) mouse study
– Gastrointestinal mouse study2
The following are required for all preclinical candidates3:
– Cardiovascular dog study
– Central nervous system mouse study
– Dose limiting toxicity (DLT)
Additional studies to address compound- or program-specific issues may be required prior to
preclinical candidate approval. These may include4,5:
– Genetic toxicity
– Repeat dose toxicity assessment
1. Berkowitz BA et al. Basic & Clinical Pharmacology. 5th ed. Norwalk, CT: Appelton & Lange; 1992:60-68.
2. Calvert Labs, Safety Pharmacology Web site. https://www.calvertlabs.com/services/safety-pharmacology/. Accessed May 20, 2010.
3. Bass A et al. J Pharmacol Toxicol Methods. 2004;49:145-151.
4. International Conference on Harmonisation Web site. http://www.ich.org/LOB/media/MEDIA4474.pdf. Accessed February 3, 2010.
5. International Conference on Harmonisation Web site. http://www.ich.org/LOB/media/MEDIA5544.pdf. Accessed February 3, 2010.
38. Pharmacokinetics vs. Pharmacodynamics
PK is a measure of compound level as a function of time
PD is a measure of target engagement as a function of time
PK and PD can differ dramatically
– Compound present but not available to target: PK > PD
– Compound has very slow off-rate, target slow turnover: PD > PK
– Active metabolite: PD > PK
PD assays
– Often used to drive preclinical development
– Important for establishing dosing in clinic and interpreting clinical results
PK = pharmacokinetic; PD = pharmacodynamic.
Ng R. Drugs: From Discovery to Approval. Wiley-LISS; 2004.
39. Module 3: How are Investigational Drugs Tested in
H
Humans?
Overall module length ~2 hours
4 Lessons
1) Clinical Development Plan
2) Phase I Trials
3) Phase II Trials
4) Phase III Trials
40.
41. Objectives of Phase I Trials
Phase I provides initial assessment of clinical safety and tolerability.
– Attention focuses on preclinical toxicology
– Identify common adverse experiences and target organ(s) of toxicity
Detailed understanding of the pharmacokinetics (“what the body does
to the drug”)
– Pharmacokinetics: the study and characterization of the time course of
drug absorption, distribution, metabolism and excretion.
Preliminary understanding of the pharmacodynamics of the drug using
relevant biomarkers (“what the drug does to the body”)
– Pharmacodynamics: the study of the relationship between dose, or
concentration of drug at the site(s) of action, and the magnitude of the
effect(s) produced.
Ultimate goal is to identify dose range and regimen for Phase II studies
based on PK and/or PD data.
42. Question 1: Determining Dosing Frequency
Once daily feasible if high levels are well tolerated, or
need to use twice daily (BID) dosing
or use controlled release (CR)
Drug Concentration
Q day dosing at 2x dose
Bid Dosing at 1x dose
Minimal effective level
by PD marker
12h 24h
43. Question 2: Food Effect
In order for drug A to be effective, it needs to achieve an AUC
of xx nM-hr. When peak concentrations are above yy nM,
subjects complain of nausea and vomiting. Here are the PK
data from Phase I including a comparison of the xx mg dose
when given fed and fasted.
How would you recommend administering the drug (what
dose, with or without food)?
What issues would concern you?
44. Question 3: Whether to Discontinue a Drug?
Reasons to kill a drug in Phase I :
Excessive toxicity
No pharmacodynamic effect
No sufficient exposure to test hypothesis
45. Common Trial Designs
Parallel Treatment A
Randomization
– Better for comparing efficacy and
Safety
Treatment B
– Shorter trial
Cross Over Treatment A Treatment B
– More power, less costly, but longer Randomization
trial
Treatment B Wash Treatment A
– Need to watch for control cross over out
effect
Adaptive
46. Phase IIa: Establishing Proof of Concept
What is proof of concept?
– Proof of pharmacology
– Role of mechanism
– Proof of clinical efficacy
– Commercial proof of concept
47. PHASE III
Phase III trials represent an enormous investment of resources.
There are a number of questions you should be confident in
answering before you make this investment.
– Have you learned enough about the drug in your Phase I and II
studies?
– Do you have agreement with the regulatory authorities on
whether your clinical program will lead to approval of the drug?
– Does the clinical program provide enough information to
adequately inform physicians
48. What are Goals of Phase III Trials?
Confirm the risk/benefit profile of the drug in large population and
specialized populations
– Is the treatment effect generalizable to larger population, subgroups?
– Is it clinically meaningful? How does it impact patients’ health, function, life-
span?
– Safety and tolerability in larger population
– How does it compare with what is currently available? Does this drug fulfill
some unmet medical need?
– Initial cost/benefit data
Provide the information needed for product labeling
49. What Does a Phase III Trial Not Answer?
Rare adverse experiences may not be detected
The effects of a drug in the real world, where its administration is not
as carefully monitored as it is in the clinical trial
Effects of concomitant medications (excluded from the Phase III trial)
Differing drug effects in subgroups of individuals (who differ by age,
gender, race, genetic background and concomitant medical
conditions...)
50. Module 4: Regulatory Review Process for New Drugs
Overall module length ~1 ½ hours
5 Lessons
1) Lesson 1: Who Regulates?
2) Lesson 2: Product Drug Labeling
3) Lesson 3: Global Regulatory Strategy
4) Lesson 4: The NDA
5) Lesson 5: FDA Review and Approval Process
51.
52. Major Regulatory Agencies
United States Food and Drug Administration (FDA)
– Extremely important agency
– Regulates the world's largest pharmaceutical market
– Very well-respected around the world; ex-US agencies are influenced by FDA decisions
European Medicines Agency (EMA)
– Pan-European regulatory agency for new drug approvals (27 nations)
– Committee for Human Medicinal Products (CHMP) provides scientific and medical
opinions for the EMA, which is the operational part of the regulatory agency
PMDA
– Japanese regulatory agency
53. Lesson 2: Product Drug Labeling
Includes all written, printed, or graphic matter accompanying an article at any time
while such article is in interstate commerce or held for sale after shipment or
delivery in interstate commerce. (i.e., paper inside the packaging) [21CFR 1.3(a)]
Prescription drug labeling is commonly called:
• Prescribing information
• Package insert
• Package leaflet
• Package circular
• Physician circular
Defined as any display of written, printed, or graphic matter on the immediate
container of any article, or any such matter affixed to a consumer commodity or
affixed to or appearing upon a package containing any consumer commodity.
[21CFR 1.3(b)]
54. Lesson 3: Global Regulatory Strategy
Regulatory agencies are responsible for protecting and promoting
their nation’s public health.
They do so by developing regulations that set a minimum
standard for the three key characteristics for evaluating a drug
• Efficacy
• Safety
• Quality - this has to do with the chemical properties, process and controls
of the manufactured product
While many country’s drug regulations are similar, there are
significant differences. These similarities and differences are the
basis of having a global regulatory strategy that strategically
encompasses the needs of all regions.
55. Module 5: Post-Approval Activities
Overall module length ~1 ¼ hours
2 Lessons
1) Lesson 1: Phases IIIb and IV
2) Lesson 2: Post Market Regulatory Activities
56. Phase IIIb & IV Post-Marketing Studies
New clinical indications
Long-term safety: including rare adverse drug reactions
Special populations
The purpose is frequently to support the marketing campaign (e.g. a
head-to-head study to demonstrate advantages, efficacy or otherwise)
57.
58. Hierarchy of Strength of Study Designs
(with Respect to Internal Validity)
Stronger
Design
Randomized experiment*
Cohort (prospective or retrospective)
Observational Research
Case-control
Cross-sectional / “ecologic” studies
Case series
Case reports
* Some place meta-analyses of clinical trials at
Weaker the top of the hierarchy
Design
58
59. REMS
Risk Evaluation and Mitigation Strategies (REMS)
– U.S. FDA specific regulation that describes the use of risk
minimization actions for drugs in the U.S.
– FDA will require a REMS when one would be necessary to
ensure that the benefits of the drug outweigh its risks
– REMS may include a range of measures
59
60. Drug Development Curriculum Implementation:
MSD-Yale-SPbSU
E-learning course The Drug Development Curriculum
(DDC):
• a pioneering initiative between Yale and Merck is planned to
be implemented in SPb State University, one of the oldest
universities in Russia
Project status
• December 2010: MSD/SPbSU joint working group started functioning
• 27-Jan-2011: the agreement is signed between MSD & SPbSU
• Mar 2011: DDC Implementation Lead & IT staff were allocated
• Mar-Apr 2011: Russian Regulatory module has been developed and incorporated into the DDC
• 25-Mar-2011 educational seminar on Drug Development process "Discovery of Gardasil" (delivered by
Dr. Eliav Barr)
• Q3-4 2011: pilot course of DDC is planned to be initiated in SPbSU; MRL tutors are desirable for
successful DDC introduction
• Sep-Oct-2011: Joined Research Day is planned to be conducted in SPbSU
61. Education Initiative
Curriculum on Drug Development (Yale pilot) being rolled out globally
Russia: St. Petersburg University (English)
• Agreement has been signed
• Separate module on Russian regulatory process being developed
China: Fuwai University Hospital (translated)
Brazil: Sao Paulo University (under discussion)
Turkey & Latin America (initial discussions)
62. Curriculum on Clinical Protocol Design
Marcelo E. Bigal, M.D., Ph.D.
Head of the Merck Investigator Studies Program and
Scientific Education Group
Office of the Chief Medical Officer
63. Opportunities Offered
Course is perfectly fit to the Yale course
• Capability transfer/education
• Plans for English and localized versions for Key Countries
Course will also support NIH task force recommendations on
pharmaceutical industry/academic center collaborations and
sharing of knowledge
Plans to roll out to key academic/medical schools
64. Description of Project
Course objective: To provide an overview of non-interventional and
interventional clinical studies with a focus on protocol design
Four proposed modules
1) Overall Principles of Clinical Research
2) Randomized Clinical Trials
3) Epidemiology Studies
4) Health Economics/Outcomes Research Studies
Content to be developed by e-learning vendor and refined by MRL
SMEs in conjunction with CMO Scientific Education Group and Merck
Polytechnic Institute